Organic Carbon Monoxide Prodrugs that Release CO Under Physiological Conditions

Structure–Photoreactivity Relationship Study of Substituted 3-Hydroxyflavones and 3-Hydroxyflavothiones for Improving Carbon Monoxide Photorelease

“…This compound has also been reported elsewhere. 81 7-Bromo-3-hydroxy-2-phenyl-4H-chromen-4-one (24). The compound was prepared according to the general procedure from 2hydroxy-4-bromoacetophenone (0.70 g, 3.25 mmol, 1.00 equiv), and benzaldehyde (1.66 mL, 16.28 mmol, 5.00 equiv) in methanol as a solvent.…”

“…The first generation of photoCORMs was based on metal–carbonyl complexes, , but several metal-free photoCORMs have already been developed, for example, based on cyclopropenone, BODIPY, or α-diketone derivatives . Today, special attention is paid to the development of photoCORMs that absorb in the near-infrared (NIR) range of 650–900 nm, known as the phototherapeutic window. , Significant developments have also been made in the field of prodrugs that release CO under physiological conditions. − …”

“… 17 , 23 Significant developments have also been made in the field of prodrugs that release CO under physiological conditions. 24 − 26 …”

Carbon Monoxide as a Potential Therapeutic Agent: A Molecular Analysis of Its Safety Profiles

“…With the discussions of CO delivery forms alternative to inhalation, it is important to note that many forms of CO donors have been developed, including metal-based CO-releasing molecules (CORMs) , and organic CO donors that are photosensitive, ROS-sensitive, ultrasound, mechanical force-sensitive, or chemoexcitation-sensitive. − There have also been efforts to develop metal-based CORMs for triggered CO release, − trapped CO, and CO solution. , In 2014, we reported the first organic CO prodrugs by taking advantage of a cheletropic reaction for CO release from a norbornadienone scaffold . This was followed by a series of reports of organic CO prodrugs of various properties, including one that uses saccharine and acesulfame as carrier molecules for CO delivery, and immobilized CO prodrugs . Among the large number of CO donors published, CORM-2, CORM-3, CORM-401, and CORM-A1 are probably the most well-known .…”

Reactive Oxygen Species-Activated Metal-Free Carbon Monoxide Prodrugs for Targeted Cancer Treatment

“…Despite its notoriety as a silent killer, carbon monoxide (CO) is actually generated endogenously in all mammals. A large number of studies have firmly established CO’s endogenous signaling roles with importance akin to NO and H 2 S . In addition to its important physiological functions, ample evidence indicates that CO also exhibits promising therapeutic potential against a wide range of human diseases, including cancer, − inflammatory bowel diseases, , and organ transplantation , among others. , For instance, CO has been reported to shrink tumors via an anti-Warburg effect, significantly potentiate chemotherapies, , and alleviate the dose-limiting toxicities of some widely used antitumor agents (i.e., doxorubicin-induced cardiotoxicity).…”